• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ChemoCentryx, Inc. - Common Stock (NQ:CCXI)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 51.97 (10)
Ask (Size) 52.00 (55)
Prev. Close 51.99
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 71,355,872
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
December 12, 2022
 
Via Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
November 23, 2022
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga

Performance

More News

Read More
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
October 17, 2022
From ChemoCentryx, Inc.
Via GlobeNewswire
Biotech Stocks Well-Positioned For The Fourth Quarter
October 12, 2022
Via Talk Markets
ChemoCentryx: Q2 Earnings Insights
August 09, 2022
Via Benzinga
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 05, 2022
From ChemoCentryx, Inc.
Via GlobeNewswire
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
September 20, 2022
Via Talk Markets
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
September 19, 2022
Via Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
Via Investor's Business Daily
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
September 13, 2022
From Scott+Scott Attorneys at Law LLP
Via Business Wire
7 Dow Stocks With Superior Fundamentals
September 06, 2022
Via InvestorPlace
Healthcare Sector Still Looks Good But Lacks Momentum
September 06, 2022
Via Talk Markets
ChemoCentryx's Return On Capital Employed Insights
September 01, 2022
Via Benzinga
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
August 30, 2022
From Scott+Scott Attorneys at Law LLP
Via Business Wire
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
August 29, 2022
Via Investor's Business Daily
Whither Small Caps After Fed’s Tough Talk?
August 29, 2022
Via Talk Markets
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
August 23, 2022
Via Investor's Business Daily
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
August 15, 2022
Via Talk Markets
Why Jim Cramer Says This Financial Stock Is 'Terrific'
August 12, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
August 10, 2022
Via Benzinga
Earnings Preview: ChemoCentryx
August 08, 2022
Via Benzinga
Small Cap Biotechs Perk Up On Dealmaking
August 06, 2022
Via Talk Markets
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
August 05, 2022
Via Investor's Business Daily
Where ChemoCentryx Stands With Analysts
August 05, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
August 05, 2022
Via Benzinga

Frequently Asked Questions

Is ChemoCentryx, Inc. - Common Stock publicly traded?
Yes, ChemoCentryx, Inc. - Common Stock is publicly traded.
What exchange does ChemoCentryx, Inc. - Common Stock trade on?
ChemoCentryx, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ChemoCentryx, Inc. - Common Stock?
The ticker symbol for ChemoCentryx, Inc. - Common Stock is CCXI on the Nasdaq Stock Market
Recent Quotes
View More
Symbol Price Change (%)
GOOG  237.49
+0.00 (0.00%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap